Acute Myeloid Leukemia News and Research

RSS
Acute Myeloid Leukemia (AML) is a rapidly progressing cancer of the blood characterized by the uncontrolled proliferation of immature blast cells in the bone marrow. The Leukemia and Lymphoma Society estimates that over 13,000 new cases of AML were diagnosed and approximately 9,000 deaths from AML occurred in the U.S. during 2007. AML is generally a disease of older adults, and the median age of a patient diagnosed with AML is about 67 years. A majority of elderly patients are not considered candidates for standard induction therapy or decline therapy, resulting in an acute need for new treatment options.
Simple, coordinated approach can improve chances of survival for high-risk AML patients

Simple, coordinated approach can improve chances of survival for high-risk AML patients

New study finds smoking cessation at any age reduces risk of death

New study finds smoking cessation at any age reduces risk of death

Cancer gene mutations can predict response to less intensive treatment in AML patients

Cancer gene mutations can predict response to less intensive treatment in AML patients

Implementation of large-scale genomic tumor profiling viable but faces several challenges

Implementation of large-scale genomic tumor profiling viable but faces several challenges

ASH partners with other organizations to address knowledge gaps in AML care

ASH partners with other organizations to address knowledge gaps in AML care

Scientists discover novel therapeutic target and treatment strategy for acute myeloid leukemia

Scientists discover novel therapeutic target and treatment strategy for acute myeloid leukemia

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Fred Hutchinson opens first-of-its-kind clinic to provide new immunotherapies for cancer patients

Nano-biointeraction and nanopathology

Nano-biointeraction and nanopathology

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Blocking critical molecule with therapeutic antibody could effectively reduce leukemia burden

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

Novel lipid-based therapeutic shows promise for combating drug resistance in AML

New oncogene may contribute to high incidence of prostate cancer among African American men

New oncogene may contribute to high incidence of prostate cancer among African American men

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

Cleveland Clinic cancer researchers receive $2.4 million grant from NIH NHLBI

Researchers awarded grant to develop safer cancer therapies for children

Researchers awarded grant to develop safer cancer therapies for children

Antibody drug offers new therapeutic approach for treating AML

Antibody drug offers new therapeutic approach for treating AML

Novel immunotherapy shows promise against AML in clinical trial

Novel immunotherapy shows promise against AML in clinical trial

HMS scientists reveal how certain tumors develop taste for fat

HMS scientists reveal how certain tumors develop taste for fat

Researchers uncover new molecular causes of brain cancer and leukemia

Researchers uncover new molecular causes of brain cancer and leukemia

Adolescent females have low rates of pregnancy screening prior to cancer treatment

Adolescent females have low rates of pregnancy screening prior to cancer treatment

New drug holds potential for treating advanced mastocytosis

New drug holds potential for treating advanced mastocytosis

Researchers find new way for early prediction of leukemic relapse

Researchers find new way for early prediction of leukemic relapse

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.